(Adnkronos) - "Terapia cellulare efficace in malattia linfoproliferativa post-trapianto correlata a Epstein Barr virus’. In studio Allele, ‘risposta nel 51% dei pazienti con una sopravvivenza di 18.4 mesi"
Category
🗞
NewsTranscript
00:00Epithelial disease or post-trapiant proliferative lymphoma are rare hematological complications
00:12that can occur after the transplantation of a solid organ or after the transplantation
00:16of hematopoietic stamina cells.
00:19The first-line therapy uses immunotherapy alone in combination with chemotherapy and
00:28can produce very good results in a good percentage of patients.
00:34Unfortunately, there is a subgroup of patients who do not respond to this first-line therapy
00:40and for whom, unfortunately, the average life expectancy is less than six months.
00:45In the subgroup of patients who do not respond to the first-line therapy or who decide after
00:53and who have a proliferative lymphoma and a correlated EBV, there is the possibility of
00:59using a new therapeutic strategy called Tablet E-Cleo-Cell.
01:04This therapy is a new therapy because it does not rely on the use of immunotherapy or chemotherapy,
01:13but on the use of anti-EBV cytotoxic T-lymphocytes obtained by healthy donors.
01:23These cells are able to recognize the cells of the disease that have integrated the Epstein-Barr virus
01:31and to isolate them.
01:33Therefore, it is possible to use this cell product in the pathology of correlated PTLD and EBV.
01:42The study published last year has shown that in the subgroup of patients
01:50who do not respond to the first-line therapy or who are resistant to the first-line therapy,
01:54in the condition of the proliferative lymphoma and the correlated EBV,
01:59it was possible, with the use of this cell product,
02:03to obtain a comprehensive response of 51% of cases
02:08and with an average of 18.4 months of survival.
02:18If, on the other hand, we do the analysis on the group of patients who have had a response,
02:25in one year we see that more than 84% of these patients are still alive,
02:31therefore with extremely promising data for this type of patients
02:37who, without this therapy, would have had an average survival of less than 6 months.
02:45The novelty of this therapy is certainly linked to the fact that it is not a chemotherapy,
02:52but a cellular therapy.
02:55It is a ready-to-use therapy, so we can take advantage of this therapy quite quickly.
03:05It is a therapy that comes to be administered in hospitals,
03:09so it does not require the recovery of the patient,
03:14and then it is a therapy that is extremely well tolerated,
03:17so even this population of patients, which is particularly fragile,
03:22has not developed significant collateral effects
03:26that have somehow blocked the use of this therapy.